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Background: Monoclonal antibodies have been employed as targeting molecules of superantigen for the
preclinical treatment of a variety of tumours. However, other targeting molecules, such as tumour-related ligands
or peptides, are less exploited. Here, we tested other targeting molecules by genetically fusing the third loop of
transforming growth factor alpha (TGFalphaL3) to mutant staphylococcal enterotoxin A (SEAD227A).
Results: The resultant fusion proteins were expressed in E. coli and purified to homogeneity through a Ni-NTA
affinity column. Fusion protein TGFalphaL3SEAD227A can promote splenocyte proliferation to a level comparable to
recombinant SEA (rSEA) and bind to EGFR-expressing tumour cells in an EGFR-dependent way. Consistent with
these observations, TGFalphaL3SEAD227A exerted an inhibitory effect on the growth of EGFR-expressing tumour
cells both in vitro and in vivo. Notably, significant infiltrations of CD8
+ and CD4
+ T cells were detected in the
tumour tissues of these C57BL/6 mice treated with TGFalphaL3SEAD227A, suggesting the involvement of T cells in
this tumour-inhibitory process.
Conclusions: The data here showed that TGFaL3 is capable of targeting superantigen to tumours and exerting an
inhibitory effect on tumour growth, which enables TGFaL3SEAD227A to be an attractive candidate for the
immunotherapy of EGFR-expressing tumours.
Background
Superantigens (SAgs) are microbial proteins with the
capacity to activate a large fraction of T cells [1]. The
cellular receptors for SAgs are major histocompatibility
complex (MHC) class II molecules and T-cell antigen
receptors (TCR) [2-4]. SAgs can bind to the TCR b
subunit and activate T cells independently of their
CD4 or CD8 phenotype when presented by MHC class
II molecules [5,6]. Activated T cells secrete a variety of
cytokines, such as TNFa,I N F g, IL-1, IL-2, IL-6, IL-8
and IL-12 [7,8]. Staphylococcal enterotoxin type A
(SEA) is a protein exotoxin secreted by certain strains
of Staphylococcus aureus, which was demonstrated to
direct cytotoxic T cells (CTLs) against MHC class II
expressing tumour cells effectively [9]. However, MHC
class II positive tumours only represent a minor frac-
tion of the most frequent human tumours. To
introduce a novel binding specificity in SEA, a mono-
clonal antibody (mAb) specific for colon carcinoma
antigen C215 was initially conjugated to SEA, and the
resultant conjugate Fab-SEA could lyse antigen expres-
sing tumour cells significantly in vitro [ 1 0 ] .T od a t e ,
SEA fused to various mAb have been subjected to pre-
clinical treatment of many tumour types, some of
which have finished phase I or phase II clinical trials,
such as C242Fab-SEA (PNU-214565) and 5T4FabV13-
SEAD227A (ABR-214936)[11-14].
EGFRs are over-expressed in a variety of human
tumour cells, including breast, head, neck, gastric, color-
ectal, oesophageal, prostate, bladder, renal, pancreatic,
ovarian and nonsmall cell lung cancer (NSCLC) [15].
Moreover, the degree of EGFR over-expression is asso-
ciated with an advanced tumour stage and resistance to
standard therapies [16-19]. EGFR-targeted therapies
have been proven to be successful by using monoclonal
antibodies (i.e. Herceptin) or tyrosine kinase inhibitors
(i.e. gefitinib). Unfortunately, not all patients bearing
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to those drugs. Only about 10% of NSCLC patients
responded clinically to gefitinib; somatic mutations
within the EGFR kinase domain were exclusively
observed in lung cancer cells in these patients [20,21].
Human transforming growth factor alpha (hTGFa)i s
a native ligand co-overexpressed with its receptor EGFR
in many human tumours [15]. hTGFa consists of three
loops, the third of which (TGFaL3) retains binding abil-
ity to EGFR but lacks mitogenic activity [22]. Binding of
TGFaL3 to EGFR is not affected by mutations in the
EGFR kinase domain, which suggests a function for
TGFaL3 as a targeting molecule, where ligand/receptor
induced internalisation is not required. Moreover, com-
pared to mAbs, TGFaL3 is presumably less antigenic,
thereby maintaining a longer circulating half-life. These
properties enable TGFaL3 to be an attractive targeting
molecule for the superantigens, which function only
when presented on the cell surface. However, the bind-
ing ability of TGFaL3 to its receptor is relatively weaker
than that of mAbs to antigen. This raises the question
whether the affinity of a small peptide is strong enough
to bring SAgs to tumours in vivo. Here, we tested this
idea by fusing TGFaL3 to SEA (D227A), a mutant of
SEA defective for MHC-II [23]. Encouragingly, we
f o u n dt h a tt h er e s u l t a n tf u s i o np r o t e i nT G F aL3-
SEAD227A c o u l db i n dt oE G F R - e x pressing tumour cells
and exhibited an apparent growth inhibitory effect on
the tumour cells, both in vitro and in vivo. T cells likely
mediated the inhibitory effect, which was suggested by
the significant infiltration of CD8
+ and CD4
+ T cells in
fusion protein-treated tumour tissues.
Results
Construction and expression of fusion proteins
To test the effect of TGFaL3 fusion on SEA (D227A)
activity, two sets of constructs, pET-22b-TGFaL3-
SEAD227A and pET-22b-SEAD227ATGFaL3, were made.
These vectors are pET-22b (+)-derived bacterial expres-
sion vectors, which drive the expression of fusion protein
TGFaL3SEAD227A, or SEAD227ATGFaL3, respectively
(Figure 1A). Constructs were transformed into E. coli
strain BL21 (DE3) and protein expression was induced by
0.5 mM IPTG. Proteins of interest with the expected
molecular weight (30 kDa) were observed in total cell pel-
lets (Figure 1B, lane 2, 3). About 55% soluble fusion pro-
teins appeared in the spheroplast when bacteria cells were
induced at 22°C (data not shown). Soluble fusion proteins
were purified from the supernatant of sonicated bacterial
pellets through a Ni-NTA affinity column. Purified pro-
teins were further dialysed against PBS and concentrated
by ultrafiltration. Coomassie blue staining after SDS-
PAGE separation showed that both TGFaL3SEAD227A and
SEAD227ATGFaL3 were purified to 95% homogeneity
(Figure 1B, lane 4, 5).
TGFaL3SEAD227A promotes splenocyte proliferation and
binds to the EGFR
To determine the proliferating effect of fusion proteins,
mice splenocytes were incubated with TGFaL3SEAD227A
or SEAD227ATGFaL3, rSEA, or PHA at 37°C for
72 hours. As showed in Figure 2A, TGFaL3SEAD227A
maintained 77.8% of the proliferative activity of
rSEA. As a control, rSEA and PHA induced strong
Figure 1 Expression and purification of fusion proteins.
(A) Schematic presentation of fusion proteins. TGFaL3 was fused to
the N-terminal or the C-terminal of SEAD227A with 8 an eight-amino
acids linker. The linker sequence (GGSGSGGG) was indicated by a
dotted rectangle. All fusion proteins were tagged with a six
histidinesix-histidine tag at the C-terminal; TGFaL3, the third loop of
TGFa; SEAD227A, site mutated SEA (D227A). (B) Expression and
purification of fusion proteins. E. coli BL21 (DE3) cells were
transformed with plasmids encoding fusion proteins, and then
induced with 0.5 mM IPTG at 22°C overnight. The proteins were
separated by a 15% SDS-PAGE gel and stained with Coomassie
blue. Lane 1, total cell proteins (TCP) of BL21 (DE3) with pET-22b
(+); lane 2, TCP of BL21 (DE3) with pET-22b-TGFaL3SEAD227A; lane 3,
TCP of BL21 (DE3) with pET-22b-SEAD227ATGFaL3; lane 4, purified
TGFaL3SEAD227A; lane 5, purified SEAD227ATGFaL3.
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Page 2 of 10Figure 2 TGFaL3SEAD227A promotes splenocyte proliferation and binds to the EGFR. (A) Superantigenic activity of the fusion proteins.
1.0 × 10
5 freshly isolated splenocytes were seeded in each well in of a 96-well plate at a density of 1.0 × 10
5 cells/well. The cells were then
incubated with 1.0 μg/ml TGFaL3SEAD227A, 1.0 μg/ml SEAD227ATGFaL3, 1.0 μg/ml rSEA, 25 μg/ml PHA or 1.0 μg/ml BSA at 37°C for 72 h, and
then MTT solution was dispensed to each well and the optical density at 570 nm was measured. Each column shows the mean ± SD of
triplicate samples. (B) The binding of fusion proteins to EGFR. A431 cells were cultured in a 96-well plate, and then fixed with 10% neutral
formaldehyde at room temperature for 1 h. The bindings of cells to various concentrations of fusion proteins were detected by cell ELSIA
(TGFaL3SEAD227A (black diamond), SEAD227ATGFaL3 (triangle), rSEA (circle). Each point shows the mean ± SD of triplicate samples. (C)
Determining the association of proteins to the EGFR via immunofluorescence staining. A431 cells were seeded on a cover glass in a 12-well
plate overnight, and then fixed with 10% neutral formaldehyde. The cells were treated with 50 ng/μl rSEA or TGFaL3SEAD227A, and subsequently
incubated with anti-hexahistidine mAb and FITC-conjugated rabbit anti-mice IgG. Bar, 8 μm. (D) Binding specificity of TGFaL3SEAD227A to A431
cells. A431 cells were seeded and treated as (C). Then 50 ng/μl EGF, TGFaL3SEAD227A, a mixture of EGF (50 ng/μl) and TGFaL3SEAD227A
(50 ng/μl), or PBS were applied to the A431 cells for two hours. After an extensive wash, cells were incubated using anti-EGF, anti-6His, or blank
control in PBS (only secondary antibody applied) treated cells. The color was then developed using a standard protocol after the secondary
antibody was applied. Bar, 50 μm.
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showed only 49.8% of the proliferative activity of rSEA,
implying that the TGFaL3 C-terminal fusion negatively
affects SEAD227A’s activity.
To investigate whether fusion proteins efficiently bind
to EGFR, A431 cells that were derived from a human
epidermoid carcinoma characterised by high levels of
EGFR expression, were incubated with different concen-
trations of 6His-tagged TGFaL3SEAD227A or SEA-
D227ATGFaL3, or rSEA (from 0.1 ng/μlt o1u g / μl). The
cells were then incubated with anti-6His tag antibody
followed by HRP conjugated anti-mouse IgG.
The results showed that both TGFaL3SEAD227A and
SEAD227ATGFaL3 bind to A431 cells with a similar affi-
nity. As a control, rSEA did not bind to A431 cells (Fig-
ure 2B). Similar results were also obtained through
immunostaining of recombinant proteins via anti-6His
antibody. TGFaL3SEAD227A predominantly localised to
the cell surface, as seen by fluorescent staining (Figure
2C). Unexpectedly, there was some punctate staining in
the cytoplasm, which seems inconsistent with the pre-
vious report that TGFaL3 is not mitogenic [22]. There
are two possible explanations:f i r s t ,t h ef u s i o np r o t e i n
could be imported into cells via an unknown mechan-
ism; second, it is artificial staining caused by fixation or
nonspecific binding.
Although both TGFaL3SEAD227A and SEAD227ATG-
FaL3 bind to EGFR more efficiently than rSEA, we still
cannot rule out the possibility that the binding of the
fusion protein to EGFR-expressing cells may not be
mediated by EGFR but by other membrane proteins. To
exclude this possibility, we conducted a ligand competi-
tion assay. As showed in Figure 2D, the binding of the
fusion protein to A431 cells can be efficiently blocked
by the addition of EGF, which binds exclusively to
EGFR. This result strongly suggests that the binding of
the fusion protein to A431 cells is mediated by its speci-
fic interaction with EGFR.
TGFaL3SEAD227A inhibited tumour cell growth in vitro
Because TGFaL3SEAD227A has stronger proliferating
activity than SEAD227ATGFaL3, we focused our inter-
est on the activity of TGFaL3SEAD227A. To test whether
TGFaL3SEAD227A bridges tumour cells and immune
effecter cells together, which then leads to the lysis of
tumour cells, A431 cells were initially co-cultured with
increasing numbers of activated spleen cells in the pre-
sence of TGFaL3SEAD227A. As shown in Figure 3A, half
inhibition of tumour cell growth by TGFaL3SEAD227A
was achieved when the effector/target (E/T) ratio was
30:1. Under this E/T ratio, we found that TGFaL3-
SEAD227A inhibits A431 cell growth in a dose-dependent
manner (Figure 3B). The third loop of human TGFa
and mouse TGFa are highly conserved (94% of
homogeneity) (Figure 3C). Further, murine melanoma
B16 cells express comparable EGFR to that found in
A431 cells (Figure 3D). This evidence suggests that
TGFaL3SEAD227A also affects EGFR-expressing mouse
tumours. Consistent with this hypothesis; the growth of
B16 cells was remarkably restrained when co-incubated
with TGFaL3SEAD227A (Figure 3E).
TGFaL3SEAD227A inhibited tumour cell growth in vivo
To test whether the peptide TGFaL3 can bring SAgs to
tumours in vivo, we evaluated the anti-tumour effect of
TGFaL3SEAD227A in mouse models. C57BL/6 mice
were subcutaneously inoculated with B16 cells. When
the length of tumours exceeded 5 mm, TGFaL3-
SEAD227A was administrated intraperitoneally four times
at one-day intervals. Tumour sizes from each mouse
were recorded at the designed intervals. Consistent with
the in vitro results, we found that all doses of TGFaL3-
SEAD227A effectively retarded tumour growth. The maxi-
mum tumour growth inhibition percentage was 84.1%,
which was observed in 60 pmol of TGFaL3SEAD227A
treated group at the 15th day (Figure 4A). As a control,
rSEA only exerted a marginal effect on tumour growth
throughout the therapeutic process (Figure 4A).
To investigate the effect of TGFaL3SEAD227A on
mouse survival, we treated mice with 60 pmol of fusion
drug identically when the tumours’ length exceeded 1
cm. The survival of mice was checked daily, and the
percent survival of the two groups were analysed by
Kaplan Meier Plot. Throughout the experiment, no
deaths were observed in the TGFaL3SEAD227A group,
while only 30% of the mice in the PBS control group
survived (Figure 4B). This data showed that TGFaL3-
SEAD227A treatment could significantly increase the sur-
vival time for tumour-bearing mice.
TGFaL3SEAD227A induced immunoresponse against
tumour cells
Recruitment of antigen-specific lymphocytes to
tumour tissue is a major goal in tumour immunother-
apy. Both CD4
+ and CD8
+ T cells were targeted by
colon cancer specific mAb conjugated SEA, to lyse
colon cancer in vivo [10]. To investigate whether
TGFaL3SEAD227A inhibited tumour growth in a simi-
lar way, we examined for infiltration of CD4
+ and
CD8
+ T cells in fusion protein-treated tumour tissue.
Not surprisingly, both CD4
+ and CD8
+ Tc e l l sw e r e
observed around the tumour tissues (Figure 5AC),
while recruitment of the same subtype of T cells was
almost non-existent in the PBS control group (Figure
5BD). These results indicated that the tumour inhibi-
tory effect induced by TGFaL3SEAD227A was, at least
partially, attributed to the infiltration of both CD4
+
and CD8
+ Tc e l l s .
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The application of SAgs for tumour therapy has been
attempted for decades. The core aim of these applica-
t i o n si st os p e c i f i c a l l yb r i ng SAgs to tumour cells via
various strategies, including tumour specific monoclonal
antibody targeted or membrane anchored SAgs
[10,24,25]. To date, mAb targeted superantigens have
been successfully applied to several types of tumours,
including B lymphocytic leukaemia, neuroblastoma,
non-small cell lung cancer, melanoma, and renal cell
carcinoma [13,26-29]. Two of them are on the way to
clinical phase trials, including C242Fab-SEA (phase I)
[14] and 5T4FabV13SEAD227A (phase II) [13]. Notably,
human anti-mouse antibody (HAMA) responses were
observed in these trials, which cause a reduced circulat-
ing half-life, thereby limiting their further use [30].
Therefore, SAgs targeting molecules with low antigeni-
city were suggested for the design of the next generation
of SAgs drugs [13].
Tumour-related ligand is less antigenic than mAbs,
and the conjugate composed of ligand and superantigen
was presumed to kill one type of tumour [31]. However,
native ligands are used less in targeting SAgs to
tumours. This is largely due to internalisation induced
by the ligand/receptor interaction, which prevents SAgs
from being presented to the surface of tumour cells and
activate T cells. To avoid the internalisation triggered by
the binding of ligand to receptor, we use a mitogenic
defective TGFa3L, instead of full length TGFa, as a tar-
geting molecule for SEAD227A. Nevertheless, the affinity
of TGFa3L with EGFR is weaker than that of full length
TGFa, which raised a concern for its ability to bring
Figure 3 TGFaL3SEAD227A inhibits tumour growth in vitro. (A) A431 cells were seeded into a 96-well plate at a density of 2.5 × 10
4 cells/well.
Following an overnight incubation period, various ratios of effector cells and target cells were co-cultured with A431 cells in the presence of 5
ng/μl rSEA(squire) or TGFaL3SEAD227A(black diamond). Viable tumour cells were determined using an MTT assay, and the data were given as a
percentage of tumour cell growth inhibition (TCGI). (B) A431 cells were plated in a 96-well plate at a density of 2.5 × 10
4 cells/well, followed by
treatment with the indicated concentrations of TGFaL3SEAD227A (black diamond) and rSEA (square) at an E/T ratio of 30:1 in vitro. Viable tumour
cells were determined as described above (A). (C) This figure indicates the alignment of the third loop of human TGFa and mice TGFa. (D)The
protein level of EGFR in A431, B16 and HEK293T cells was detected by western blotting. (E) B16 cells, plated in a 96-well plate at a density of 2.5
×1 0
4, were treated identically to the A431 cells with the indicated dose of TGFaL3SEAD227A (black diamond), rSEA(square), and BSA (triangle).
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Page 5 of 10superantigen to the tumour in vivo. As shown in this
paper, TGFaL3SEAD227A can inhibit tumour growth in
a EGFR-dependent way, implying that the affinity of
TGFaL3 is sufficient for targeting the superantigen to
the tumour. Meanwhile, we also noticed a decreased
therapeutic effect of the fusion protein when a higher
dose of fusion protein (600 pmol) was applied. This
indicates that high dose treatment may result in
increased nonspecific binding which eventually counter-
acts the tumour inhibitory effect of the fusion protein.
The affinity of TGFaL3 to tumour should be further
improved for better targeting efficiency. Despite that,
the therapeutic effect of TGFaL3SEAD227A is still
encouraging, especially when the dose was limited to
concentrations between 6 pmol and 60 pmol.
The antigenicity of TGFaL3SEAD227A is presumably
lower than its monoclonal antibody orthologs. To test
this hypothesis, the surviving mice in the TGFaL3-
SEAD227A treated group (at day 24 in the survival ratio
test) were bled before being sacrificed and ELISA was
used to detect antibodies against proteins of interest. No
detectable titre was found in either high and low doses
of TGFaL3SEAD227A-treated groups (data not shown).
This result showed that the injection procedure for
fusion protein in this paper could not induce apparent
antibodies against these two proteins. However, we are
not sure whether the same result will occur in the case
of injection with a higher dose of fusion protein. It was
reported that SAgs, including SEA and SEB, could act as
an adjuvant to enhance humoral immunity via activating
antigen specific CD4
+ T cells [32]. This observation
raises the possibility that a higher dose of TGFaL3-
SEAD227A may boot the antibody against itself, owing to
the adjuvant effect of SEA. To this end, we increased
the injection dose to 1 mg and extended the interval
between injections to two weeks. After three intramus-
cular injections, the titres of antibody against the pro-
teins of interest were determined. As shown in Figure
6A, considerable titres of antibodies against
both TGFaL3SEAD227A and rSEA were observed.
Figure 4 TGFaL3SEAD227A inhibits tumour growth in vivo.
(A) Thirty C57BL/6 mice were inoculated subcutaneously with 1.0 ×
10
6 B16 melanoma cells. When the tumour length exceeded 0.5 cm,
the mice were separated into equal-size groups and injected
intraperitoneally with 6 pmol (asterisk), 60 pmol (multiplication), 600
pmol TGFaL3SEAD227A (black triangle), 60 pmol rSEA(black square)
or PBS (black diamond), respectively, four times at one day intervals.
The tumour sizes were measured with callipers at the time points
indicated. The tumour volumes were calculated as (length ×
width
2)/2. Each point shows the mean ± SD of the tumour volume
from ten treated mice. (B) Twenty mice were inoculated with 1.0 ×
10
6 B16 melanoma cells each and then randomised into two
groups. The mice were treated with 60 pmol TGFaL3SEAD227A (black
diamond) or PBS (black square) according to the protocol above
when the tumour length exceeded 1 cm. The survival percentages
were analysed by Kaplan Meier Plot.
Figure 5 TGFaL3SEAD227A recruits T cells to the tumour tissue.
Tumour tissues were excised from mice treated with 60 pmol
TGFaL3SEAD227A or PBS after 24 days. The histochemical samples
were prepared in a standard way, followed by staining with
antibodies against the CD4 molecule (A and B) or the CD8
molecule (C and D). CD4
+ and CD8
+ T cells in the PBS control
group were shown in figure 5B and 5 D, respectively; CD4
+ and
CD8
+ T cells in the TGFaL3SEAD227A group are shown in figure 5A
and 5C, respectively.
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can also recognise TGFaL3 (Figure 6B). These observa-
tions confirmed the adjuvant property of SEA, indicating
the inevitable antigenicity of superantigen macromole-
cules. Therefore, to reduce the antigenicity of SAgs
macromolecules, the optimisation of both drug dose and
treatment procedure will be very important when a pre-
clinical trial is designed. Recently, it was reported that
combinational use of Fab-SAgs fusion proteins with
docetaxel not only improved the antitumour efficiency
of Fab-SAgs but also reduced the production of
anti-SEA antibody [33,34]. This finding provides another
strategy to eliminate the antigenicity of SAgs
macromolecules.
Conclusions
The results in this paper showed that human TGFa-
derived TGFaL3 is capable of directing SAgs to tumours
and exerting an inhibitory effect on tumour growth,
which makes TGFaL3SEAD227A an attractive candidate
for immunotherapy on EGFR-expressing tumours.
Methods
Bacterial strains and Cell culture
Escherichia coli strain DH5a was used for plasmid pro-
pagation and cloning. Strain BL21 (DE3) (Novagen,
Madison, WI, USA) was used as a host for the produc-
tion of fusion proteins. A431 (epidermoid carcinoma)
and B16 (a murine melanoma cell line) cells were main-
tained in Dulbecco’s Modified Eagle medium (DMEM)
(Gibco BRL, Life Technology, Rockville, MD) supple-
mented with 10% foetal bovine serum (FBS) (Gibco
BRL, Life Technology, Rockville, MD), 2 mM L-gluta-
mine, 100 units/ml penicillin and 100 mg/ml streptomy-
cin. Mouse spleen cells, freshly separated from healthy
C57BL/6 mice, were grown in DMEM/F12 cell culture
medium.
Plasmid Construction
A site mutation (D227A) in the SEA gene was intro-
duced by PCR-amplification. This mutation resulted in
the defective binding of SEA to the MHC-II molecule
[23]. To avoid potential conformational perturbation
caused by the fusion, an eight-amino acid flexible linker
was also introduced between SEAD227A and TGFaL3.
The primers for the PCR reaction include Primer 1, 5’-
AA GGA TCC GGT GGT GGT AGC GAG AAA
AGC-3’,a n dP r i m e r2 ,5 ’-ATG AAT TCA CTC GAG
ACT TGT ATA TAA ATA TAT AGC AAT ATG
CAT-3’. The PCR product was purified and digested
w i t hB a m HIa n dX h oI .T h ed i g e s t e dS E A D227A gene
was inserted into the pET-22b (+) vector (Novagen,
Madison, WI, USA) to produce the plasmid pET-
SEAD227A.T of u s eT G F aL3 to the N terminal of
SEAD227A, Primers 3 and 4 were annealed and extended
(Primer 3: 5’-AA CAT ATG GTA TGC CAC TCT
GGT TAC GTT GGC GCA CGT TGT GAA CAC-3’;
Primer 4: 5’-TT GGA TCC AGA ACC ACC GAG CAG
GTC AGC GTG TTC ACA ACG TGC GCC -3’). The
resultant products were then digested by Nde I and
BamH I and ligated into pET-22b-SEAD227A cut with
the same restriction enzymes. The resultant recombi-
nant vector was termed pET-22b-TGFaL3SEAD227A,
and encodes TGFaL3 and SEAD227A, plus an
Figure 6 The antigenicity evaluation of TGFaL3SEAD227A.N i n e
mice were randomised into three groups and injected
intramuscularly with 1 mg TGFaL3SEAD227A, rSEA, or PBS,
respectively. The injections were repeated three times at two-week
intervals. Then serum from each group was collected and analysed
as follows. (A) To detect the antigenicity of TGFaL3SEAD227A (square)
or rSEA (triangle), the corresponding proteins were coated on ELISA
plates. The titres of antibody were detected in the standard way.
(B) To analyse the antigen epitopes recognised by the
TGFaL3SEAD227A antibody, the native ligand TGFa (square), rSEA
(triangle), or BSA(circle)was coated and the anti-serum of
TGFaL3SEAD227A was analysed in the same way as (A).
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(Figure 1A).
To evaluate the influence of the TGFaL3 fusion direc-
tion on protein activity, another plasmid pET-22b-SEA-
D227ATGFaL3 was also generated, in which the TGFaL3
coding sequence was induced to the 3’-terminal of the
SEA gene. First, a Sac I site was introduced into the
3’-terminal of the SEA gene by PCR using Primer 1 and
Primer 5 (Primer 5: 5’-AA GTG GTG GAG CTC GAC
ACT TGT A-3’) and the PCR product was cloned into
pET-22b, resulting in plasmid pET-22b-SEAD227ASacI.
Then the cDNA encoding TGaL3 plus the eight-linker
was generated by annealing and extending Primers 6
and 7 (Primer 6: 5’-AA GAG CTC GGT GGT GGT
TCT GGT GGT GGT TCT GTA TGC CAC TCT GGT
TAC GTT GGC-3’;P r i m e r7 :5 ’-AA CTC GAG GAG
CAG GTC AGC GTG TTC GCA ACG TGC GCC
AAC GTA ACC AGA GTG GCA -3’). The extension
product and pET-22b-SEAD227ASacI were doubly
digested by Sac I and Xho I and then ligated together.
The resultant vector was named pET-22b-SEAD227A
TGFaL3 (Figure 1A). All DNA constructs were con-
firmed by DNA sequencing. Both constructs were
expected to express fusion proteins with 266 amino
acids (aa), including TGFaL3 (17 aa), mutated SEA (233
aa), linker sequence (8 aa), C-terminal histidine tag (6
aa), and two amino acids (LE) before the histidine tag
encoded by the restriction enzyme recognising sequence
for cloning.
Expression and purification of fusion proteins
Construct pET-22b-TGFaL3SEAD227A or pET-22b-SEA-
D227ATGFaL3 was transformed into BL21 (DE3) and
then induced with 0.5 mM IPTG at 22°C overnight. The
cell pellet was washed and suspended in binding buffer
(0.5 mol/l NaCl, 0.1 mol/l Tris.Cl, pH8.0), followed by a
regular sonication procedure. The cell debris was
removed by centrifugation at 12,000 g for 30 min. The
supernatant was then applied to Ni-charged chelating-
Sepharose (Pharmacia Biotech, Uppsala, Sweden). After
being washed with binding buffer plus 80 mM imida-
zole, the fusion protein was eluted with the binding buf-
fer containing 250 mM imidazole and then dialysed
against PBS buffer overnight. Fusion proteins were
enriched by ultrafiltration and quantified by BCA assay
(Pierce, Rockford, USA).
Splenocyte proliferation assay
Splenocytes freshly isolated from the spleen of healthy
C57BL/6 mice were seeded into 96-well plates at a den-
sity of 1 × 10
5 cells per well in the presence of
1.0 μg/ml TGFaL3SEAD227A,1 . 0μg/ml SEAD227ATG-
FaL3, 1.0 μg/ml rSEA, 25 μg/ml phytohemagglutinin
(PHA) or 1.0 μg/ml BSA. The treated cells were
cultured at 37°C for 72 h, then 20 μl5m g / m l3 - ( 4 ,5 -
dimethylthiazol-2-μl)-2, 5- diphenyltetrazolium bromide
(MTT) was added for another 4 h. Finally, 150 μl
dimethyl sulphoxide (DMSO) was dispensed into each
well and the optical density at 570 nm was measured on
an ELISA reader (Biorad 550). The relative proliferating
activity of the fusion protein was given by % 100 ×
OD570 of the fusion protein/OD570 of the rSEA.
Cell ELISA assay
Binding of TGFaL3SEAD227A or SEAD227ATGFaL3 to
EGFR was detected by cell ELISA [35]. Briefly, 1 × 10
4
A431 cells per well were partitioned into 96-well flat-
bottomed plates overnight, then fixed with 10% neutral
formaldehyde (10 mmol/l PBS, 10% formaldehyde,
pH7.4) at room temperature for 1 h. The cells were
blocked with 5 mg/mL bovine serum albumin (BSA) for
2 h and incubated with different concentrations of
TGFaL3SEAD227A,S E A D227ATGFaL3 or rSEA at 37°C
for 1 h. After being washed five times with PBST (10
mmol/l PBS pH7.4, 0.05%Tween-20), the cells were
incubated with anti-hexahistidine MAb (1:1250), fol-
lowed by HRP-conjugated rabbit anti-mice IgG (1:5000)
and washed as previously. Finally, the colour was devel-
oped by 0.4 mg/ml orthopenylenediamine (OPD) solu-
tion with 1.5% H2O2, and the absorbance at 490 nm was
analysed on ELISA reader.
In vitro Tumour cell growth inhibition assay
Tests were performed according to the previously
described method [36]. B16 cells or A431 cells in
DMEM medium were added at a density of 2.5 × 10
4
cells/well to 96-well flat-bottomed plates, followed by
treatment with the indicated reagents and effector cells
to a total volume of 100 μl. Cells were cultured for 72 h
at 37°C in 5% CO2. The remaining viable tumour cells
were determined using the MTT assay. The data were
given as the percentage of tumour cell growth inhibition
(%TCGI), which was calculated as the following: %TCGI
=1 0 0×( A test-Ab)/(Ac-Ab). Atest is the absorbance of
tumour cells grown in the presence of the effector cells
and various reagents, Ac is the absorbance of the
tumour cells grown in the medium, and Ab is the absor-
bance of the medium only.
In vivo tumour inhibition assay
C57BL/6 mice (4-6 weeks old) were obtained and main-
tained at the certified animal facility of Beijing Institute
of Biotechnology. Fifty mice were inoculated subcuta-
neously with 1.0 × 10
6 B16 cells suspended in PBS plus
1% C57BL/6 mouse serum. When the tumour length
exceeded 0.5 cm, the mice were randomly divided into
five groups (10 mice per group) and subsequently
injected intraperitoneally with 6 pmol (L), 60 pmol (M),
Xu et al. BMC Biotechnology 2010, 10:91
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four times at one day intervals. Tumour size was mea-
sured with calipers at the time points indicated. The
tumour volume was calculated as (length × width
2)/2
[37]. The tumour growth inhibition ratio was calculated
as % 100 × (tumour volume of PBS control-tumour
volume of interest)/tumour volume of PBS. The survival
p e r c e n t a g e so fm i c ew e r ea n a l y s e db yK a p l a nM e i e r
Plot. All animal experiments were designed and con-
ducted according to the recommendations of the Beijing
Experimental Animal Regulation Board (SYXK/JING/
2005/0031).
Western blotting and Immunohistochemical analysis
Western blot analysis was performed routinely with the
EGFR monoclonal antibody (Santa Cruz Biotechnology,
Inc) or anti-ß actin polyclonal antibody (Santa Cruz Bio-
technology, Inc). For immunohistochemical analysis, the
tumour tissues from sacrificed mice were embedded in
paraffin after being fixed with 10% formaldehyde in PBS
(pH7.4). The sections were stained with mouse anti-
CD4 (1:500) or anti-CD8 mAbs (1:400) (Millipore,
Upstate, MA, USA) at 4°C overnight, followed by bioti-
nylated secondary antibody (1:5000) for 10 min at room
temperature. Finally, the colour was developed in a stan-
dard way.
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